RemeGen Co Ltd
SSE:688331

Watchlist Manager
RemeGen Co Ltd Logo
RemeGen Co Ltd
SSE:688331
Watchlist
Price: 100.82 CNY -1.63% Market Closed
Market Cap: ¥56.8B

Net Margin

-42.5%
Current
Improving
by 63.7%
vs 3-y average of -106.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-42.5%
=
Net Income
¥-947.6m
/
Revenue
¥2.2B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-42.5%
=
Net Income
¥-947.6m
/
Revenue
¥2.2B

Peer Comparison

Country Company Market Cap Net
Margin
CN
RemeGen Co Ltd
SSE:688331
57.8B CNY
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
173.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 90% of companies in China
Percentile
10th
Based on 8 721 companies
10th percentile
-42.5%
Low
-416 945.9% — -1.5%
Typical Range
-1.5% — 8.9%
High
8.9% — 17 382.1%
Distribution Statistics
China
Min -416 945.9%
30th Percentile -1.5%
Median 3.5%
70th Percentile 8.9%
Max 17 382.1%

RemeGen Co Ltd
Glance View

Market Cap
56.8B CNY
Industry
Biotechnology

In the bustling landscape of China's biopharmaceutical industry, RemeGen Co Ltd stands as a beacon of innovation and determination. Founded in 2008 and headquartered in Yantai, the company swiftly positioned itself as a frontrunner in the development of novel biologic therapies. With its operation straddling cutting-edge research and development facilities and state-of-the-art production capabilities, RemeGen focuses on addressing unmet medical needs in the realms of oncology and autoimmune diseases. Their work fundamentally consists of harnessing the power of human biology to create targeted therapies, a task which involves a rigorous process of discovery, clinical trials, and regulatory approvals before a drug can be brought to market. The company's business model relies significantly on its ability to advance promising candidates through the clinical pipeline and secure partnerships with international pharmaceutical giants. This not only helps in sharing the financial risks associated with drug development but also accelerates market access for its therapies. Revenue streams for RemeGen primarily come from sales of its proprietary drugs, licensing agreements, and milestone payments tied to research achievements or commercial successes. By aligning with global standards for drug development, RemeGen not only nurtures its own product portfolio but also attracts strategic collaborations, making it a formidable player in the global life sciences ecosystem.

Intrinsic Value
38.96 CNY
Overvaluation 61%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-42.5%
=
Net Income
¥-947.6m
/
Revenue
¥2.2B
What is RemeGen Co Ltd's current Net Margin?

The current Net Margin for RemeGen Co Ltd is -42.5%, which is above its 3-year median of -106.3%.

How has Net Margin changed over time?

Over the last 3 years, RemeGen Co Ltd’s Net Margin has decreased from 14.7% to -42.5%. During this period, it reached a low of -143.7% on Jun 30, 2023 and a high of 14.7% on Aug 30, 2022.

Back to Top